Related Experiment Video
Updated: Jan 17, 2026
Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient
George Nassief1, Tolulope Adeyelu2, Andrew Elliott2
1Division of Medical Oncology, Department of Medicine, Washington University in Saint Louis, Saint Louis, MO.
Purpose:
Homologous recombination deficiency (HRD) results in DNA instability in tumor cells and contributes to tumor pathogenesis. Although HRD-directed therapies are established in other cancers, their role in skin cancers remains unclear. Given the poor response to standard therapies in skin cancer subtypes like acral and mucosal melanoma, we aimed to characterize the prevalence of HRD across skin cancer subtypes, evaluate its correlation with immune checkpoint inhibitor (ICI) response biomarkers, and assess its prognostic relevance in patients treated with immunotherapy (IO).
Methods:
A total of 2,508 patients with skin cancer underwent molecular profiling including whole-exome sequencing, whole-transcriptome sequencing, and immunohistochemistry. HRD status was defined by a high loss of heterozygosity (LOH-high) or mutations in homologous recombination repair (HRR) genes. Associations between HRD and established ICI biomarkers (tumor mutational burden, PD-L1, deficient mismatch repair/microsatellite instability-high, immune cell fractions, and transcriptomic signatures) were assessed. Survival outcomes on ICI therapy were assessed in cutaneous melanoma using insurance claims data.
Results:
Overall, among the melanoma subtypes, mucosal and acral melanoma had a greater prevalence of LOH-high than cutaneous (30.9% v 13.1% v 8.3%, P < .001). Generally, LOH-high in skin cancer did not correlate with mutations in HRR genes. Additionally, there was no significant association in ICI response biomarkers and HRD among patients with skin cancers. Furthermore, HRD was not associated with a prognostic advantage following IO (hazard ratio, 0.981 [CI, 0.80 to 1.20]; P = .854).
Conclusion:
HRD defines a biologically distinct subset of skin cancers and is not predictive of ICI response or improved outcomes. The high prevalence of HRD in acral and mucosal melanoma highlights the need to investigate HRD-directed therapies strategies in this distinct cohort, such as poly (ADP-ribose) polymerase inhibitors or platinum-based therapies.
Related Concept Videos
01:20Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
01:36Mismatch Repair
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
01:08Nucleotide Excision Repair
02:53Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...